Moderna misses Q4 EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake challenges.
Latest Ratings for MRNA
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Deutsche Bank | Maintains | Hold | |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Feb 2022 | SVB Leerink | Maintains | Underperform |
